《国际循环》：“选择最佳联合是科学而不是艺术”的发言是非常好的优秀的演讲。您能否用两三句话简单总结一下为个体患者选择何种联合策略？

     <International Circulation>:The speech on “Choosing the optimal combination is a science， not an art” is a very nice and excellent presentation. Could you just conclude what the strategy is for choosing a combination for individual patients in two or three sentences?

    Williams教授：我认为，我说的第一点是因为大多数卒中激活肾素-血管紧张素系统，因此肾素-血管紧张素系统阻滞应是联合治疗的一部分。目前，我认为血管紧张素受体阻断剂是耐受更好的肾素-血管紧张素系统阻滞剂，因此我会在联合策略中包括这种药物。然后，我们可以选择利尿剂或CCB，我认为对多数患者来说，CCB是优选的联合，因其不良反应较少，且治疗问题较少。但一些患者会需要利尿剂，如果他们有水肿的话。   

    Prof. Williams： I think the first point that I made was that because most strokes activate the renin-angiotensin system， and the renin-angiotensin system blockade has to be part of the combination of treatment. I think at the moment， the angiotensin receptor blockers are the better tolerated blockers of the renin-angiotensin system， so I would include those in a combination. And then we have the option of either diuretic or CCB， and I think for most people， a CCB is a preferred combination because it has less side effects and less problems with treatment. But some people will need diuretic if they have edema.